Processing, Please wait...

  • Publisher Home
  • Home
  • ๐Ÿ”™ Back
  • ๐Ÿ“š Journals
    • โš™๏ธ IJIEC - Industrial Engineering Computations
    • ๐ŸŒ IJDNS - Data and Network Science
    • ๐Ÿงช CCL - Current Chemistry Letters
    • ๐Ÿ’น AC - Accounting
    • ๐ŸŽฏ DSL - Decision Science Letters
    • ๐Ÿš› USCM - Uncertain Supply Chain Management
    • ๐Ÿ—๏ธ JPM - Journal of Project Management
    • ๐Ÿฅ HE - Healthcare Engineering
    • ๐Ÿ“ˆ SCI - Scientometrica
    • ๐Ÿ”ฉ ESM - Engineering Solid Mechanics
    • ๐ŸŒฟ JFS - Journal of Future Sustainability
    • ๐Ÿ’ผ MSL - Management Science Letters
  • ๐Ÿ“ Submit Article
  • ๐Ÿ“Š Statistics
  • ๐Ÿ“‹ About
    • ๐Ÿ“„ About Us
    • ๐Ÿ“ฐ Blog
    • ๐Ÿ“ข News
    • ๐Ÿ“ง Contact
  • ๐Ÿ“บ Tutorial
  • Search:
  • Advanced Search

Growing Science » Tags cloud » Type 2 diabetes

โญ Highly Cited Articles

  • Jaya Algorithm
  • Rao Algorithm
  • TLBO Algorithm
  • ChatGPT and Blended Learning

Journals

  • IJIEC (840)
  • IJDS (1032)
  • DSL (759)
  • ESM (434)
  • CCL (563)
  • JPM (350)
  • AC (572)
  • JFS (106)
  • MSL (2658)
  • USCM (1104)
  • HE (55)
  • SCI (53)

๐Ÿ”‘ Keywords

Jordan(175)
Supply chain management(172)
Vietnam(154)
Customer satisfaction(124)
Performance(117)
Supply chain(115)
Artificial intelligence(108)
Service quality(101)
Competitive advantage(100)
SMEs(95)
Tehran Stock Exchange(94)
Sustainability(94)
optimization(88)
Financial performance(86)
TOPSIS(85)
Trust(85)
Genetic Algorithm(81)
Organizational performance(81)
Job satisfaction(81)
Knowledge Management(80)


» Show all keywords

โœ๏ธ Authors

Naser Azad(82)
Zeplin Jiwa Husada Tarigan(70)
Mohammad Reza Iravani(65)
Endri Endri(45)
Hotlan Siagian(43)
Muhammad Alshurideh(42)
Dmaithan Almajali(39)
Jumadil Saputra(37)
Muhammad Turki Alshurideh(35)
Ahmad Makui(33)
Sautma Ronni Basana(33)
Barween Al Kurdi(32)
Basrowi Basrowi(31)
Mohammad Khodaei Valahzaghard(30)
Haitham M. Alzoubi(30)
Ni Nyoman Kerti Yasa(30)
Hassan Ghodrati(30)
Shankar Chakraborty(29)
Sulieman Ibraheem Shelash Al-Hawary(28)
Mahmoud Allahham(28)


» Show all authors

๐ŸŒ Countries

1. Algeria (52)
2. Angola (2)
3. Argentina (22)
4. Armenia (2)
5. Australia (52)
6. Austria (2)
7. Bahrain (26)
8. Bangladesh (58)
9. Belarus (4)
10. Belgium (3)
11. Benin (2)
12. Benin Republic (1)
13. Bhutan (1)
14. Bosnia and Herzegovina (1)
15. Botswana (9)
16. Brazil (40)
17. Brunei (1)
18. Bulgaria (1)
19. Burkina Faso (1)
20. Cameroon (1)
Total: 121 countries

Show all countries
Sort articles by: ๐Ÿ“– Volume | ๐Ÿ“… Date | โญ Most Rates | ๐Ÿ‘๏ธ Most Views | ๐Ÿš€ Rising Stars | ๐Ÿ”— Citations (Scopus) | ๐Ÿ”ฅ Hot Papers
1.

A scientometric survey of the emerging research landscape on orforglipron, an oral non-peptide GLP-1 receptor agonist Pages 115-124 PDF Download PDF

Authors: Mina Bagheriyan

doi 10.5267/j.sci.2025.4.003

๐Ÿ”‘ Keywords: Orforglipron, GLP-1 Receptor Agonist, Type 2 Diabetes, Obesity, Oral Pharmacotherapy, Scientometric Analysis

Abstract:
The worldwide prevalence of type 2 diabetes (T2D) and obesity has been a driving force behind the heavy research on glucagon-like peptide-1 receptor agonists (GLP-1RAs). Orforglipron, an innovative, oral, non-peptide GLP-1RA, is a major development in the therapeutic field, and it has the potential to make the delivery of drugs easier and more patient-friendly than the usual injections. The purpose of this scientometric study is to present the scientific works on orforglipron and thus portray its research landscape, important topics, and growing evidence base. A detailed examination of 101 scientific works (from 2023 to 2025) taken from the Scopus database has been done in this study. The documents were divided into categories depending on the type (e.g., clinical trial, review, meta-analysis), the theme dealt with, and the writer's background. The synthesis included research trends in focus, drug efficacy and safety outcomes, and positioning of the drug within the larger area of pharmacotherapy. The literature on orforglipron has just begun, with the first publications coming out in 2023. The data set consists of a substantial primary research foundation comprising clinical trials of all three Phases, plus a great number of reviews, meta-analyses, and editorial commentaries. The major research themes are: (1) Efficacy in Type 2 Diabetes and obesity, showing pronounced drops in HbA1c and body weight; (2) Safety and tolerability, where the main concern is with gastrointestinal adverse events; (3) Comparative effectiveness against other GLP-1RAs and multi-agonists; (4) Pharmacological characterization as a small-molecule agonist; and (5) The potential role of the drug in cardiovascular risk reduction and other areas that are yet to be explored. The scientific literature surrounding orforglipron is growing at a rapid pace and this indicates that there is a high interest in the drug's potential to change the management of T2D and obesity. The current evidence places it as a powerful, oral option to be administered instead of GLP-1RAs that are delivered by injection. The future research initiatives will probably be directed towards the investigation of the long-term cardiovascular outcomes, real-world effectiveness, and the use in a broader range of patients with different diseases.
Details
  • 0
  • 1
  • 2
  • 3
  • 4
  • 5

Journal: SCI | Year: 2025 | Volume: 1 | Issue: 3 | Views: 525

 
2.

A Scientometrics survey of GLP-1 receptor agonists in neurodegenerative disorders: An evolving paradigm from metabolic to brain health Pages 125-134 PDF Download PDF

Authors: Nastaran Makoui

doi 10.5267/j.sci.2025.4.004

๐Ÿ”‘ Keywords: GLP-1 receptor agonist, Neurodegeneration, Alzheimer's disease, Parkinson's disease, Obesity, Type 2 diabetes, Scientometrics, Neuroprotection, Semaglutide, Liraglutide

Abstract:
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally designed for the management of type 2 diabetes (T2DM) and weight loss, have turned out to be a potential therapeutic target for neurodegenerative diseases. The present scientometrics study carries out a detailed analysis of 119 scienctific studies to the front of publications in the Scopus database (2011-2026) and maps the academic structure, thematic development, and main research areas in this rapidly growing field. The examination points out a strong increase in the number of publications, particularly from 2022 onward, which marks a major paradigm shift in considering GLP-1 RAs as possible neuroprotectors. Among the main research areas are: (1) Mechanistic Preclinical Studies, which account for the majority of publications and explain insulin signaling, neuroinflammation, oxidative stress, apoptosis and synaptic plasticity through the different pathways; (2) Clinical and Real-World Evidence, comprising of retrospective cohort studies and the first randomized controlled trials (RCTs) that show a decrease in dementia and Parkinson's disease (PD) among T2DM patients; (3) Drug-Specific Investigations, that discuss the effects of liraglutide, semaglutide, exendin-4, and the dual agonist tirzepatide; and (4) Disease-Specific Applications, primarily concentrating on Alzheimer's disease (AD) and PD. The field is characterized by a powerful shift from animal models to human trials and is starting to test applications in other areas besides the classic neurodegeneration such as cognitive dysfunction in obesity, psychiatric disorders and other CNS conditions. This survey encapsulates the present knowledge, puts the limelight on the contributions of pivotal Ais and research groups, and points out the future directions for this very promising area of therapeutic development.
Details
  • 0
  • 1
  • 2
  • 3
  • 4
  • 5

Journal: SCI | Year: 2025 | Volume: 1 | Issue: 3 | Views: 650

 

® 2010-2026 GrowingScience.Com